OpZira Raises $2M Seed for Ophthalmic Diagnostics

OpZira Secures $2M Seed Round

OpZira, a Pennsylvania-based ophthalmic medical device company, has raised $2 million in seed funding. The round was announced on September 15, 2026. No lead investor or participating investors were disclosed.

What OpZira Does

OpZira builds diagnostic tools for the early detection and monitoring of ocular disease, with a focus on age-related macular degeneration (AMD). The company was formed in 2025 out of LumiThera's diagnostic product lines following Alcon's acquisition of LumiThera.

OpZira's current offerings include:

• AdaptDx Pro – a wearable dark adaptometer used for the early detection and monitoring of ocular disease.
• An electrophysiology vision-testing platform – a diagnostic system for assessing visual function.

The company is also developing AI-driven quantitative diagnostics, extending its existing product portfolio into automated, data-driven analysis.

Leadership

OpZira is led by president and CEO Clark E. Tedford, who co-founded LumiThera. Tedford's background in ophthalmic diagnostics and his role in building LumiThera's diagnostic business provide continuity as OpZira establishes itself as a standalone company.

Market Context

Age-related macular degeneration is a leading cause of vision loss, and early detection is critical for monitoring disease progression and guiding treatment decisions. Diagnostic tools that can identify functional changes in the retina before structural damage becomes apparent may offer clinical advantages in managing AMD and other ocular diseases.

OpZira's product lines—particularly the AdaptDx Pro and its electrophysiology platform—are already commercialized, giving the company a revenue-generating base as it pursues AI-driven diagnostic development. The spin-out from LumiThera's diagnostic division means OpZira inherits established technology and clinical relationships rather than starting from scratch.

Funding Details

• Round type: Seed
• Amount: $2,000,000 USD
• Announced: September 15, 2026
• Lead investor: Not disclosed
• Investors: Not disclosed

The seed round provides OpZira with capital to support its diagnostic product lines and advance its AI-driven quantitative diagnostics initiatives. The company has not publicly stated specific allocation plans for the proceeds.

Strategic Perspective

For acquirers and strategic partners in the ophthalmic device space, OpZira represents a focused asset with an existing commercial footprint and a pipeline aimed at quantitative, AI-enabled diagnostics. The company's origin—carved out of LumiThera's diagnostic lines after Alcon's acquisition—positions it as a pure-play diagnostics entity, distinct from the therapeutic side of the eye care market.

With a seed-stage raise and a leadership team drawn from LumiThera, OpZira is at an early stage of its standalone trajectory. The combination of marketed hardware (AdaptDx Pro, electrophysiology platform) and in-development AI diagnostics suggests a dual strategy: sustain near-term revenue while building next-generation capabilities.

What to Watch

• Progress on AI-driven quantitative diagnostics and any regulatory milestones.
• Commercial traction for the AdaptDx Pro and electrophysiology platform.
• Additional financing or strategic partnerships as the company scales.
• Any further disclosures about the seed round's investor base.

OpZira's $2 million seed round marks its first publicly announced financing as an independent company. The funding supports its mission to improve early detection and monitoring of ocular disease, with AMD as a primary focus.